Pfizer discontinues development of danuglipron for chronic weight management Ruchika Sharma14 April 2025 5:41 PM ISTNew York: Pfizer Inc. has announced the company has discontinued the development of danuglipron (PF-06882961), an oral glucagon-like...
Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market Ruchika Sharma23 Dec 2024 5:01 PM ISTPfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated to be worth about $150...
Pfizer advances development of once-daily formulation of Oral GLP-1 Receptor Agonist Danuglipron Ruchika Sharma14 July 2024 10:00 AM ISTNew York: Pfizer Inc. has announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its...
Pfizer drops twice daily version of obesity pill over side effects Ruchika Sharma2 Dec 2023 4:24 PM ISTNew York: Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after...
Pfizer scraps once-a-day experimental obesity pill over liver safety concerns Ruchika Sharma27 Jun 2023 2:30 PM ISTNew York: Pfizer Inc said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue...
Oral diabetes drug Danuglipron achieves similar weight loss as Ozempic injection: JAMA Medha Baranwal24 May 2023 11:15 AM ISTUSA: Danuglipron demonstrated a safety and efficacy profile in tune with peptidic glucagon-like peptide 1 receptor agonists in type 2 diabetes (T2D)...
